At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMLX Amylyx Pharmaceuticals
Trading 02-06 13:06:37 EST
13.87
+0.88
+6.77%
High13.87Low13.27Vol275.98K
Open13.35D1 Closing12.99Amplitude4.62%
Mkt Cap1.52BTradable Cap907.78MTotal Shares109.82M
T/O3.75MT/O Rate0.42%Tradable Shares65.45M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Amylyx Co-CEO Justin B. Klee Reports Sale of Common Shares
Reuters  ·  02-05 05:05
Amylyx Co-CEO Justin B. Klee Reports Sale of Common Shares
Amylyx Co-CEO Joshua B. Cohen Reports Disposal of Common Shares
Reuters  ·  01-21
Amylyx Co-CEO Joshua B. Cohen Reports Disposal of Common Shares
Amylyx Pharmaceuticals (AMLX) Valuation Check After AMX0318 Rare Disease Pipeline Update
Simply Wall St.  ·  01-12
Amylyx Pharmaceuticals (AMLX) Valuation Check After AMX0318 Rare Disease Pipeline Update
Amylyx Co-CEO Justin Klee Reports Sale of Common Shares
Reuters  ·  01-09
Amylyx Co-CEO Justin Klee Reports Sale of Common Shares
Amylyx Pharmaceuticals Nominates AMX0318 as Candidate to Treat Post-Bariatric Hypoglycemia
MT Newswires Live  ·  01-08
Amylyx Pharmaceuticals Nominates AMX0318 as Candidate to Treat Post-Bariatric Hypoglycemia
Amylyx selects AMX0318 as development candidate for PBH
TIPRANKS  ·  01-08
Amylyx selects AMX0318 as development candidate for PBH
Amylyx Pharmaceuticals Advances AMX0318 as Long-Acting GLP-1 Receptor Antagonist for Rare Diseases
Reuters  ·  01-08
Amylyx Pharmaceuticals Advances AMX0318 as Long-Acting GLP-1 Receptor Antagonist for Rare Diseases
Amylyx Pharmaceuticals Announces Nomination of Amx0318 as a Novel, Long-Acting Glp-1 Receptor Antagonist Development Candidate, Identified in Collaboration With Gubra a/S
THOMSON REUTERS  ·  01-08
Amylyx Pharmaceuticals Announces Nomination of Amx0318 as a Novel, Long-Acting Glp-1 Receptor Antagonist Development Candidate, Identified in Collaboration With Gubra a/S
Amylyx Pharmaceuticals Inc - Gubra to Receive Over $50 Mln in Milestones and Royalties
THOMSON REUTERS  ·  01-08
Amylyx Pharmaceuticals Inc - Gubra to Receive Over $50 Mln in Milestones and Royalties
Assessing Amylyx Pharmaceuticals (AMLX) Valuation After Insider Buying And AMX0114 Trial Progress
Simply Wall St.  ·  01-05
Assessing Amylyx Pharmaceuticals (AMLX) Valuation After Insider Buying And AMX0114 Trial Progress
Director Karen Firestone Acquires Common Shares of Amylyx Pharmaceuticals Inc
Reuters  ·  2025-12-24
Director Karen Firestone Acquires Common Shares of Amylyx Pharmaceuticals Inc
Is Amylyx Pharmaceuticals (AMLX) Overvalued After Its 250% Year‑to‑Date Share Price Surge?
Simply Wall St.  ·  2025-12-10
Is Amylyx Pharmaceuticals (AMLX) Overvalued After Its 250% Year‑to‑Date Share Price Surge?
BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies
Reuters  ·  2025-12-06
BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies
BUZZ-Amylyx rises after promising early-stage trial for ALS drug
Reuters  ·  2025-12-05
BUZZ-Amylyx rises after promising early-stage trial for ALS drug
BRIEF-Amylyx Pharmaceuticals Announces New Safety And Tolerability Cohort 1 Data Of Amx0114
Reuters  ·  2025-12-05
BRIEF-Amylyx Pharmaceuticals Announces New Safety And Tolerability Cohort 1 Data Of Amx0114
Amylyx Reports Positive Early Safety Data for AMX0114 in ALS Phase 1 LUMINA Trial
Reuters  ·  2025-12-05
Amylyx Reports Positive Early Safety Data for AMX0114 in ALS Phase 1 LUMINA Trial
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of Amx0114 in ALS From First-in-Human Lumina Trial
THOMSON REUTERS  ·  2025-12-05
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of Amx0114 in ALS From First-in-Human Lumina Trial
Amylyx Pharmaceuticals Inc - Amx0114 Well-Tolerated With No Serious Adverse Events
THOMSON REUTERS  ·  2025-12-05
Amylyx Pharmaceuticals Inc - Amx0114 Well-Tolerated With No Serious Adverse Events
Amylyx Pharmaceuticals Chief Medical Officer Camille L. Bedrosian Reports Disposal of Common Shares
Reuters  ·  2025-12-04
Amylyx Pharmaceuticals Chief Medical Officer Camille L. Bedrosian Reports Disposal of Common Shares
Amylyx Pharmaceuticals Q3 EPS USD -0.37 Vs. IBES Estimate USD -0.47
Reuters  ·  2025-11-20
Amylyx Pharmaceuticals Q3 EPS USD -0.37 Vs. IBES Estimate USD -0.47

Introduction

Company Name.
Amylyx Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Issue price:
--